Why a Compounded GLP-1 Can Feel Weaker: 8 Things to Check Before You Blame the Batch

Quick answer: when a new vial of compounded semaglutide or tirzepatide doesn't seem to work like the last one, the explanation is often something you can check: the concentration changed (so your usual units now hold less drug), the vial was exposed to heat in shipping or storage, the vial is past its 28-day window, your timing shifted, or your body's response changed over time. Product quality can also vary; compounded drugs aren't FDA-approved, and the FDA doesn't review them for quality before they're sold. Don't change how much you take on your own. Gather the details below and talk to your prescriber and the dispensing pharmacy.

This is a common complaint in GLP-1 communities, and it's worth taking seriously, but systematically. Here's how.

Educational only, not medical advice. This article explains what can affect how a medication seems to work and how to check it. It doesn't recommend any dose, product, pharmacy or change to your treatment. Dose decisions belong to your prescriber.

1. Did the concentration change?

This is the first thing to check, because it's the most common and the easiest to confirm. A syringe unit is a volume; the amount of drug in it depends on the vial's concentration. If your new vial is 2.5 mg/mL and your old one was 5 mg/mL, the same unit count now holds half as much drug.

Math only: 20 units = 0.2 mL. At 5 mg/mL that's 1 mg; at 2.5 mg/mL it's 0.5 mg.

Compare the two labels carefully, including ratios like "10 mg/2 mL" (which is 5 mg/mL). Our guide on recalculating units for a new vial walks through it, and why units don't equal mg explains the underlying math. If the concentration changed and your instructions didn't, call the pharmacy before your next dose.

2. Was the vial kept cold?

Injectable GLP-1s need refrigeration, and peptides in solution are sensitive to heat. The FDA says it has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs, and it recommends not using an injectable GLP-1 that arrives warm or without enough refrigeration, because this can affect quality.

Ask yourself: did the package arrive cold? Did the vial spend time in a hot car, a sunny window or a fridge door that swings in temperature? Did it freeze at the back of the fridge? A degraded product can look perfectly normal. See our storage guide.

3. Is the vial past its window?

The FDA recommends discarding compounded multi-dose GLP-1 vials within 28 days after first use, even if medication remains and even if the compounder's instructions say longer. Using a vial past its beyond-use date raises contamination risk, and there's no assurance it keeps its strength. Check when you first punctured it.

4. Are you measuring the same way?

• New syringes? A switch from a 0.5 mL barrel (1-unit ticks) to a 1 mL barrel (2-unit ticks) changes how you read the scale. A switch to a U-40 syringe changes the volume of every mark. See our syringe units guide.
• Air bubbles take up space the scale counts as liquid.
• Dead space in a detachable-needle syringe holds liquid that never gets delivered.

5. Did your timing change?

Moving your injection day, missing a dose or spacing doses irregularly can change how you feel, especially toward the end of the week. Your prescriber can tell you how your specific medication should be timed and what to do if you miss one; brand labels give specific missed-dose instructions.

6. Has your response changed over time?

People often describe the first weeks after starting, or after a dose change, as the period of the strongest appetite effects, with the effect feeling less dramatic later. A feeling that "it stopped working" can also reflect normal changes over a long course of treatment, such as weight plateaus, rather than anything about the vial. That's a conversation for your prescriber, who may look at your progress over months rather than days.

7. Is it the product itself?

This is a real possibility, and the FDA's concerns about unapproved GLP-1 drugs describe several quality issues:

• Compounded drugs are not FDA-approved, and the agency doesn't review them for safety, effectiveness or quality before marketing.
• Salt forms. The FDA says some compounded semaglutide may be made from salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the approved drugs, and that it has no information on whether they have the same chemical and pharmacologic properties.
• Fraudulent products. The FDA reports compounded semaglutide and tirzepatide with false labels, including pharmacy names that don't exist or didn't make the product, and counterfeit Ozempic.
• "Research use" products. The FDA has warned companies selling GLP-1s labeled "for research purposes" or "not for human consumption" to consumers, and says those products are of unknown quality.

If you suspect a product problem:

• Ask the pharmacy about the batch, the active ingredient (base or salt form) and whether anything changed.
• Check the pharmacy's license with your state board of pharmacy.
• Ask whether a certificate of analysis or batch testing is available. Our guide to reading a COA explains what a real one shows (and what it doesn't).
• Report quality problems to FDA MedWatch.

8. Is it something else entirely?

Diet, sleep, stress, illness, new medications, alcohol and changes in activity all affect appetite and weight, sometimes more than week-to-week differences in a vial. Your prescriber can help sort this out, especially if you can show them what changed and when.

What to bring to your prescriber

The most useful conversation is a specific one:

• The old and new vial labels: concentration, pharmacy, dates.
• When you started the new vial and when you first noticed a change.
• What changed: appetite, side effects, weight trend, energy.
• Your doses: amount, units drawn, dates, and any missed or late ones.
• Storage or shipping issues: did anything arrive warm?

Don't increase your dose on your own to compensate for a vial that feels weaker. If the problem is actually a concentration change or a measuring error, "making up for it" can mean taking much more than intended; the FDA has reported people drawing five to 20 times their intended dose of compounded semaglutide.

Tracking it in Caliper

Caliper saves each vial separately with its concentration, reconstitution or opened date and use-by date, so a switch to a new vial is visible in your history. Dose logs record the amount, units and mL drawn and the injection site, side-effect logs are linked to doses, and weight trends sit on the same timeline, so you can see whether a change lines up with a new vial or something else. When it's time to talk to your provider, Caliper can create a PDF summary of your protocol, dose timeline, weight trend, side effects and injection sites, which you can email or share straight from your phone. Caliper doesn't judge whether a product is working or suggest a dose; it gives you and your provider the facts.

FAQ

Why does my new vial of compounded tirzepatide feel weaker?

Common checkable causes include a change in concentration (so the same units hold less drug), heat exposure during shipping or storage, using a vial past 28 days, measuring differences and changes in timing. Product quality can also vary. Talk to your prescriber and pharmacy before changing anything.

Can compounded semaglutide be weaker than Ozempic or Wegovy?

Compounded drugs aren't FDA-approved, so their quality isn't reviewed by the FDA before marketing, and the FDA has raised concerns about salt forms and fraudulent products. That doesn't mean any given product is weaker, but it does mean there's less assurance. Discuss options with your prescriber.

Should I take more if my vial feels weaker?

Not on your own. If the cause is a concentration change or a measuring mistake, taking more can mean a much larger dose than intended. Ask your prescriber and pharmacy first.

What are semaglutide salt forms?

Semaglutide sodium and semaglutide acetate are salt forms the FDA says some compounders have used. The FDA says they're different active ingredients from those in the approved drugs and that it doesn't know whether they behave the same way.

My compounded GLP-1 arrived warm. Can I use it?

The FDA recommends not using any injectable GLP-1 that arrives warm or with insufficient refrigeration. Contact the pharmacy.

How do I report a problem with a compounded medication?

Tell the dispensing pharmacy and your prescriber, and report quality problems or adverse events to FDA MedWatch.

The takeaway

When a vial "feels weaker," work through it calmly: concentration, cold chain, 28-day window, measurement, timing, your own response, and only then the product. Write down what you find, don't adjust your dose yourself, and bring the specifics to your prescriber and pharmacy.

Sources

• FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA, Dosing errors associated with compounded injectable semaglutide products
• American Diabetes Association, Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: a statement
• FDA, MedWatch: safety information and adverse event reporting

Make the math (and the record-keeping) automatic

Caliper is a private, local-first tracker for GLP-1 and peptide protocols. You record the amount you took and it logs each dose with one tap, reminds you when the next one is due, tracks vials with reconstitution and use-by dates, and keeps injection sites, side effects and weight trends on one timeline. Your health data stays on your device, and Caliper never recommends or calculates a dose; it organizes what you and your provider decide.

Start tracking your vials and doses with Caliper →

For adults 18+.

---

Medical disclaimer: This article is for general educational purposes only and is not medical advice. It does not recommend any dose, dilution, compound, product, supplier or protocol. Always follow your prescriber's instructions and the product label, and talk to a pharmacist or healthcare provider about any question regarding your medication, its preparation, storage, measurement or administration.